Gary Ulaner, MD, PhD, FSNMMI, FACNM

GU Oncology Now

Gary Ulaner, MD, PhD, FACNM, is the Director of Molecular Imaging and Therapy at Hoag Family Cancer Institute, as well as a Clinical Professor of Radiology and Translational Genomics, Keck School of Medicine, University of Southern California.Dr. Ulaner sat down with us to highlight the line(s) of therapy in which novel RLT-PSMA agents are being developed.In what line(s) of therapy are novel RLT-PSMA agents being developed?Dr. Ulaner: So, Pluvicto is FDA approved late in the course of disease for patients who have progressed on hormonal and prior taxane chemotherapy, as was described in the patient population in the VISION trial. There are multiple clinical trials that are investigating the use of these PSMA targeted agents earlier in the course of disease. Trials that come to mind are the ECLIPSE trial, the SPLASH trial, the ARROW trial, that are utilizing different keys to bind to PSMA that are labeled with Lutetium-177. Or in the case of the ARROW trial, Iodine-131, earlier in the course of disease, in patients that have progressed on hormonal therapies, but have yet to be challenged by chemotherapies.And certainly, patients are looking to become part of these trials because it gives them the option to use the PSMA targeted therapies instead of using chemotherapies. Which have, in my experience, and the experience of many other people, far greater toxicities than these PSMA targeted radioligand therapies. So the opportunity for patients to use the radioligand therapies earlier than chemotherapy, I think, is a big advance.View Dr. Ulaner&rsquo;s comments on <a href="https://guoncologynow.com/post/molecular-imaging-and-therapy-in-prostate-cancer" target="_blank" rel="noopener">Molecular Imaging and Therapy in Prostate Cancer</a> as well as <a href="https://guoncologynow.com/post/safety-and-efficacy-of-177lu-psma-617" target="_blank" rel="noopener">Safety and Efficacy of 177Lu-PSMA-617</a>.

RLT-PSMA in Development

Radioligand therapy prostate-specific membrane antigen

Dr. Ulaner highlights the lines of therapy in which novel RLT-PSMA agents are being developed.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe